Literature DB >> 2232806

Neoadjuvant Cis-DDP in esophageal cancers: an experience at a regional cancer centre, India.

S K Murthy1, P S Prabhakaran, M Chandrashekar, R Deshpande, D C Doval, K S Gopinath.   

Abstract

We are analysing the results of 80 patients who underwent surgery during 1983-84 for esophageal cancer. Forty patients who received pre-operative single agent Cis-DDP were grouped under "A" and 40 patients who went for surgery directly were grouped under "B". Twenty-two patients (55%) of Group A showed tumor necrosis. Both groups underwent resection and hand-sewn anastamosis of the esophagus. There were 10 post-operative deaths among 80 resected cases, 9 of them being from anastomatic leak. Cis-DDP has induced negligible side effects. A comparatively high survival rate during early years in patients who responded to Cis-DDP suggests that neoadjuvant chemotherapy might be of value.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2232806     DOI: 10.1002/jso.2930450308

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.

Authors:  F Mühr-Wilkenshoff; W Hinkelbein; I Ohnesorge; K J Wolf; E-O Riecken; M Zeitz; H Scherübl
Journal:  Int J Colorectal Dis       Date:  2003-02-01       Impact factor: 2.571

Review 2.  Molecular mechanisms associated with chemoresistance in esophageal cancer.

Authors:  Matheus Lohan-Codeço; Maria Luísa Barambo-Wagner; Luiz Eurico Nasciutti; Luis Felipe Ribeiro Pinto; Nathalia Meireles Da Costa; Antonio Palumbo
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.